[SRAHEC] Evolving Epidemics: Fentanyl, Xylazine, and Stimulant Use Disorders

Nabarun Dasgupta

doi:10.17615/kmn8-t492

August 29, 2026Open Access

[SRAHEC] Evolving Epidemics: Fentanyl, Xylazine, and Stimulant Use Disorders

View Full Paper

Ask AI

Bookmark

Share

Key Points

Review the evolving clinical and epidemiological dynamics surrounding fentanyl, xylazine contamination, and stimulant use disorders.
Synthesized public health surveillance and clinical updates presented to the Southern Regional Area Health Education Center in North Carolina.
Characterizes the clinical risks associated with the proliferation of synthetic opioids combined with non-opioid sedatives such as xylazine.
Identifies the rising management complexity of concurrent stimulant use disorder within communities impacted by polysubstance contamination.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical review highlights the evolving dynamics of fentanyl, xylazine, and stimulant co-use, underscoring complex challenges in substance use disorder management.

Abstract

Presentation to SR-AHEC North Carolina

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nabarun Dasgupta (2026) studied this question.

synapsesocial.com/papers/6a93f1266c1a8fb52e79ddc6 https://doi.org/10.17615/kmn8-t492

View Full Paper

Ask AI

Bookmark

Share

[SRAHEC] Evolving Epidemics: Fentanyl, Xylazine, and Stimulant Use Disorders

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

[SRAHEC] Evolving Epidemics: Fentanyl, Xylazine, and Stimulant Use Disorders

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading